Wang et al. developed an experimental cancer vaccine that simultaneously introduced an mRNA encoding a melanoma-associated antigen, tyrosinase-related protein 2 (TRP2), and a PDL-1 blocking siRNA into the APCs. The gene discussed is DCT; the disease is cancer.